Aug. 19 at 11:23 AM
$CRMD the market is recognizing that, while the raise and acquisition have damaged the growth prospects of CRMD, and added a substantial risk, the base product DefendCath has the capacity to carry the load a bit higher. While I thought we would be at 30 by year end, I now think we could see 20. And closer in time, the current run should take us to mid 13’s. We were at 17 briefly before this acquisition. Even Wainwright, the kiss of death investment banking firm dropped our projections but retained the buy rating. Melinta may turn out to be a positive, but the recent turn to profitability is typically short lived in a company recently auctioned.
